BLX-0631

N/A

Report date: 2023/10/24 16:05:12
NME

Base Information

Drug NameBLX-0631
Drug Alias NameBLX-0631BLX 0631
ClassificationSmall molecules
Mechanisms of ActionProto-oncogene serine/threonine-protein kinase Pim-1 modulator
TargetsProto-oncogene serine/threonine-protein kinase Pim-1
Therapy Area/IndicationsLupus Erythematosus, SystemicMultiple MyelomaCarcinoma, Renal Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBiolexis Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBiolexis Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicMultiple MyelomaCarcinoma, Renal Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A